{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:32:23Z","timestamp":1793431943379,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40123-020-00280-8","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T15:03:26Z","timestamp":1595689406000},"page":"889-911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":163,"title":["Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody\u2013Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study"],"prefix":"10.1007","volume":"9","author":[{"given":"Asim V.","family":"Farooq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Degli Esposti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praneetha","family":"Thulasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Zaugg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf Z.","family":"Badros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bennie H.","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Opalinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"January","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Piontek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Colby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"key":"280_CR1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"280_CR2","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"YT Tai","year":"2015","unstructured":"Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187\u201399.","journal-title":"Immunotherapy"},{"key":"280_CR3","unstructured":"National Cancer Institute. Surveillance, epidemiology, and end results program. cancer stat facts: myeloma; 2020. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"280_CR4","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"280_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","volume":"20","author":"J Mikhael","year":"2020","unstructured":"Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:1\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"280_CR6","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"280_CR7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321.","journal-title":"Lancet Oncol"},{"key":"280_CR8","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641\u201353.","journal-title":"Lancet Oncol"},{"key":"280_CR9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","volume":"9","author":"S Trudel","year":"2019","unstructured":"Trudel S, Lendvai N, Popat R, et al. Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9:37.","journal-title":"Blood Cancer J"},{"key":"280_CR10","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"Y-T Tai","year":"2014","unstructured":"Tai Y-T, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128\u201338.","journal-title":"Blood"},{"key":"280_CR11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.HS9.0000560524.63281.bc","volume":"3","author":"R Montes De Oca","year":"2019","unstructured":"Montes De Oca R, Bhattacharya S, Vitali N, et al. The anti-BCMA antibody-drug conjugate GSK2857916 drives immunogenic cell death and immune-mediated anti-tumor responses, and in combination with an OX40 agonist potentiates in vivo activity. HemaSphere. 2019;3:231.","journal-title":"HemaSphere"},{"key":"280_CR12","doi-asserted-by":"crossref","unstructured":"Lonial S, Lee HC, Badros A, et al. Pivotal DREAMM-2 study: single-agent belantamab mafodotin (GSK2857916) in patients with relapsed\/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and\/or intolerant to anti-CD38 monoclonal antibodies (mAbs). 25th European Haematology Association Annual Congress; June 11\u201314, 2020; Virtual.","DOI":"10.1200\/JCO.2020.38.15_suppl.8536"},{"key":"280_CR13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31:589\u2013604.","journal-title":"J Ocul Pharmacol Ther"},{"key":"280_CR14","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. Rockwell, MD: National Cancer Institute; 2009. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40."},{"key":"280_CR15","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/j.clbc.2018.03.005","volume":"18","author":"EO Kreps","year":"2018","unstructured":"Kreps EO, Derveaux T, Denys H. Corneal changes in trastuzumab emtansine treatment. Clin Breast Cancer. 2018;18:e427\u2013e429429.","journal-title":"Clin Breast Cancer"},{"key":"280_CR16","doi-asserted-by":"crossref","unstructured":"Lee BA, Lee MS, Maltry AC, Hou JH. Clinical and histological characterization of toxic keratopathy from depatuxizumab mafodotin (ABT-414), an antibody-drug conjugate: [RETRACTED]. Cornea. 2018.","DOI":"10.1097\/ICO.0000000000001635"},{"key":"280_CR17","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.2011.39.4403","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Kim S, Romaguera J, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed\/refractory B-cell lymphoma. J Clin Oncol. 2012;30:2776\u201382.","journal-title":"J Clin Oncol"},{"key":"280_CR18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10549-019-05179-y","volume":"175","author":"E Deklerck","year":"2019","unstructured":"Deklerck E, Denys H, Kreps EO. Corneal features in trastuzumab emtansine treatment: not a rare occurrence. Breast Cancer Res Treat. 2019;175:525\u201330.","journal-title":"Breast Cancer Res Treat"},{"key":"280_CR19","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","volume":"32","author":"NM Tannir","year":"2014","unstructured":"Tannir NM, Forero-Torres A, Ramchandren R, et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs. 2014;32:1246\u201357.","journal-title":"Invest New Drugs"},{"key":"280_CR20","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1097\/ICO.0000000000000868","volume":"35","author":"M Tsuda","year":"2016","unstructured":"Tsuda M, Takano Y, Shigeyasu C, Imoto S, Yamada M. Abnormal corneal lesions induced by trastuzumab emtansine: an antibody-drug conjugate for breast cancer. Cornea. 2016;35:1378\u201380.","journal-title":"Cornea"},{"key":"280_CR21","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e346346.","journal-title":"Lancet Oncol"},{"key":"280_CR22","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/neuonc\/nox202","volume":"20","author":"HK Gan","year":"2018","unstructured":"Gan HK, Reardon DA, Lassman AB, et al. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro Oncol. 2018;20:838\u201347.","journal-title":"Neuro Oncol"},{"key":"280_CR23","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1158\/1078-0432.CCR-18-0481","volume":"24","author":"JA Thompson","year":"2018","unstructured":"Thompson JA, Motzer RJ, Molina AM, et al. Phase I trials of anti-ENPP3 antibody-drug conjugates in advanced refractory renal cell carcinomas. Clin Cancer Res. 2018;24:4399\u2013406.","journal-title":"Clin Cancer Res"},{"key":"280_CR24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/ICO.0000000000001805","volume":"38","author":"E Corbelli","year":"2019","unstructured":"Corbelli E, Miserocchi E, Marchese A, et al. Ocular toxicity of mirvetuximab. Cornea. 2019;38:229\u201332.","journal-title":"Cornea"},{"key":"280_CR25","doi-asserted-by":"crossref","unstructured":"Clinical and histological characterization of toxic keratopathy from depatuxizumab mafodotin (ABT-414), an antibody-drug conjugate: retraction. Cornea. 2018;37:e55.","DOI":"10.1097\/ICO.0000000000001737"},{"key":"280_CR26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","volume":"8","author":"H Donaghy","year":"2016","unstructured":"Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8:659\u201371.","journal-title":"MAbs"},{"key":"280_CR27","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.31304","volume":"124","author":"GD Goss","year":"2018","unstructured":"Goss GD, Vokes EE, Gordon MS, et al. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. Cancer. 2018;124:2174\u201383.","journal-title":"Cancer"},{"key":"280_CR28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/neuonc\/noy091","volume":"21","author":"AB Lassman","year":"2019","unstructured":"Lassman AB, van den Bent MJ, Gan HK, et al. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro Oncol. 2019;21:106\u201314.","journal-title":"Neuro Oncol"},{"key":"280_CR29","first-page":"965","volume":"19","author":"DA Reardon","year":"2017","unstructured":"Reardon DA, Lassman AB, van den Bent M, et al. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro Oncol. 2017;19:965\u201375.","journal-title":"Neuro Oncol"},{"key":"280_CR30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10637-016-0419-7","volume":"35","author":"GI Shapiro","year":"2017","unstructured":"Shapiro GI, Vaishampayan UN, LoRusso P, et al. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Invest New Drugs. 2017;35:315\u201323.","journal-title":"Invest New Drugs"},{"key":"280_CR31","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00280-017-3451-1","volume":"80","author":"M van den Bent","year":"2017","unstructured":"van den Bent M, Gan HK, Lassman AB, et al. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemother Pharmacol. 2017;80:1209\u201317.","journal-title":"Cancer Chemother Pharmacol"},{"key":"280_CR32","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","volume":"20","author":"U Banerji","year":"2019","unstructured":"Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20:1124\u201335.","journal-title":"Lancet Oncol"},{"key":"280_CR33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","volume":"20","author":"JS de Bono","year":"2019","unstructured":"de Bono JS, Concin N, Hong DS, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:383\u201393.","journal-title":"Lancet Oncol"},{"key":"280_CR34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clml.2015.12.004","volume":"16","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, Lioure B, Kim SK, et al. A phase II study of coltuximab ravtansine (SAR3419) monotherapy in patients with relapsed or refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2016;16:139\u201345.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"280_CR35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","volume":"147","author":"LP Martin","year":"2017","unstructured":"Martin LP, Konner JA, Moore KN, et al. Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRalpha-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017;147:402\u20137.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"280_CR36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","volume":"157","author":"DM O'Malley","year":"2020","unstructured":"O'Malley DM, Matulonis UA, Birrer MJ, et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020;157(2):379\u201385.","journal-title":"Gynecol Oncol"},{"key":"280_CR37","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.2017.168401","volume":"103","author":"M Trneny","year":"2018","unstructured":"Trneny M, Verhoef G, Dyer MJ, et al. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. 2018;103:1351\u20138.","journal-title":"Haematologica"},{"key":"280_CR38","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","volume":"25","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Birrer MJ, O'Malley DM, et al. Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine. Clin Cancer Res. 2019;25:1727\u201336.","journal-title":"Clin Cancer Res"},{"key":"280_CR39","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1002\/cncr.27622","volume":"118","author":"M Beeram","year":"2012","unstructured":"Beeram M, Krop IE, Burris HA, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer. 2012;118:5733\u201340.","journal-title":"Cancer"},{"key":"280_CR40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1158\/1078-0432.CCR-13-0580","volume":"20","author":"V Ribrag","year":"2014","unstructured":"Ribrag V, Dupuis J, Tilly H, et al. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2014;20:213\u201320.","journal-title":"Clin Cancer Res"},{"key":"280_CR41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2016.02.008","volume":"40","author":"BE de Goeij","year":"2016","unstructured":"de Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol. 2016;40:14\u201323.","journal-title":"Curr Opin Immunol"},{"key":"280_CR42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","volume":"200","author":"PK Mahalingaiah","year":"2019","unstructured":"Mahalingaiah PK, Ciurlionis R, Durbin KR, et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther. 2019;200:110\u201325.","journal-title":"Pharmacol Ther"},{"key":"280_CR43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00003226-200101000-00016","volume":"20","author":"Z Liu","year":"2001","unstructured":"Liu Z, Carvajal M, Carraway CA, Carraway K, Pflugfelder SC. Expression of the receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in human ocular surface epithelia. Cornea. 2001;20:81\u20135.","journal-title":"Cornea"},{"key":"280_CR44","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","volume":"78","author":"H Zhao","year":"2018","unstructured":"Zhao H, Atkinson J, Gulesserian S, et al. Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates. Cancer Res. 2018;78:2115\u201326.","journal-title":"Cancer Res"},{"key":"280_CR45","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048\u201360.","journal-title":"Clin Cancer Res"},{"key":"280_CR46","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.icu.0000143688.45232.15","volume":"15","author":"DA Hollander","year":"2004","unstructured":"Hollander DA, Aldave AJ. Drug-induced corneal complications. Curr Opin Ophthalmol. 2004;15:541\u20138.","journal-title":"Curr Opin Ophthalmol"},{"key":"280_CR47","doi-asserted-by":"crossref","first-page":"15863","DOI":"10.1038\/ncomms15863","volume":"8","author":"E Bernitt","year":"2017","unstructured":"Bernitt E, Dobereiner HG, Gov NS, Yochelis A. Fronts and waves of actin polymerization in a bistability-based mechanism of circular dorsal ruffles. Nat Commun. 2017;8:15863.","journal-title":"Nat Commun"},{"key":"280_CR48","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1158\/1535-7163.MCT-16-0710","volume":"16","author":"H Zhao","year":"2017","unstructured":"Zhao H, Gulesserian S, Ganesan SK, et al. Inhibition of megakaryocyte differentiation by antibody-drug conjugates (ADCs) is mediated by macropinocytosis: implications for ADC-induced thrombocytopenia. Mol Cancer Ther. 2017;16:1877\u201386.","journal-title":"Mol Cancer Ther"},{"key":"280_CR49","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1167\/iovs.16-21111","volume":"58","author":"H Peng","year":"2017","unstructured":"Peng H, Park JK, Lavker RM. Autophagy and macropinocytosis: keeping an eye on the corneal\/limbal epithelia. Invest Ophthalmol Vis Sci. 2017;58:416\u201323.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"280_CR50","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2147\/IJN.S196681","volume":"14","author":"N Nagai","year":"2019","unstructured":"Nagai N, Ogata F, Otake H, Nakazawa Y, Kawasaki N. Energy-dependent endocytosis is responsible for drug transcorneal penetration following the instillation of ophthalmic formulations containing indomethacin nanoparticles. Int J Nanomedicine. 2019;14:1213\u201327.","journal-title":"Int J Nanomedicine"},{"key":"280_CR51","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/microorganisms7090351","volume":"7","author":"MR Pennington","year":"2019","unstructured":"Pennington MR, Saha A, Painter DF, et al. Disparate entry of adenoviruses dictates differential innate immune responses on the ocular surface. Microorganisms. 2019;7:351.","journal-title":"Microorganisms"},{"key":"280_CR52","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000298751","volume":"224","author":"T Guthoff","year":"2010","unstructured":"Guthoff T, Tietze B, Meinhardt B, Becher J, Guthoff R. Cytosine-arabinoside-induced keratopathy: a model of corneal proliferation kinetics. Ophthalmologica. 2010;224:308\u201311.","journal-title":"Ophthalmologica"},{"key":"280_CR53","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4252\/wjsc.v6.i4.391","volume":"6","author":"JJ Yoon","year":"2014","unstructured":"Yoon JJ, Ismail S, Sherwin T. Limbal stem cells: central concepts of corneal epithelial homeostasis. World J Stem Cells. 2014;6:391\u2013403.","journal-title":"World J Stem Cells"},{"key":"280_CR54","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1111\/bph.14429","volume":"175","author":"HP Lin","year":"2018","unstructured":"Lin HP, Singla B, Ghoshal P, et al. Identification of novel macropinocytosis inhibitors using a rational screen of food and drug administration-approved drugs. Br J Pharmacol. 2018;175:3640\u201355.","journal-title":"Br J Pharmacol"},{"key":"280_CR55","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood.V126.23.1328.1328","volume":"126","author":"AT Fathi","year":"2015","unstructured":"Fathi AT, Borate U, DeAngelo DJ, et al. A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in adults with relapsed or refractory B-lineage acute leukemia (B-ALL) and highly aggressive lymphoma. Blood. 2015;126:1328.","journal-title":"Blood"},{"key":"280_CR56","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V126.23.182.182","volume":"126","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Fanale MA, Shah BD, et al. 182 A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in relapsed\/refractory B-lineage non-Hodgkin lymphoma. Blood. 2015;126:182.","journal-title":"Blood"},{"key":"280_CR57","first-page":"1957","volume":"31","author":"RJ Cenedella","year":"1990","unstructured":"Cenedella RJ, Fleschner CR. Kinetics of corneal epithelium turnover in vivo. Studies of lovastatin. Invest Ophthalmol Vis Sci. 1990;31:1957\u201362.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"280_CR58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/bs.pmbts.2015.04.001","volume":"134","author":"AO Eghrari","year":"2015","unstructured":"Eghrari AO, Riazuddin SA, Gottsch JD. Overview of the cornea: structure, function, and development. Prog Mol Biol Transl Sci. 2015;134:7\u201323.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"280_CR59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0039-6257(96)00007-0","volume":"41","author":"MD Wagoner","year":"1997","unstructured":"Wagoner MD. Chemical injuries of the eye: current concepts in pathophysiology and therapy. Surv Ophthalmol. 1997;41:275\u2013313.","journal-title":"Surv Ophthalmol"},{"key":"280_CR60","doi-asserted-by":"crossref","first-page":"110009","DOI":"10.1016\/j.biopha.2020.110009","volume":"125","author":"SS Bashraheel","year":"2020","unstructured":"Bashraheel SS, Domling A, Goda SK. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. Biomed Pharmacother. 2020;125:110009.","journal-title":"Biomed Pharmacother"},{"key":"280_CR61","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/CCO.0000000000000296","volume":"28","author":"J Antoun","year":"2016","unstructured":"Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol. 2016;28:288\u201394.","journal-title":"Curr Opin Oncol."},{"key":"280_CR62","doi-asserted-by":"crossref","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","volume":"4","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, et al. Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019;4:e000491.","journal-title":"ESMO Open."},{"key":"280_CR63","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","volume":"50","author":"O Huillard","year":"2014","unstructured":"Huillard O, Bakalian S, Levy C, Desjardins L, Lumbroso-Le Rouic L, Pop S, et al. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur J Cancer. 2014;50:638\u201348.","journal-title":"Eur J Cancer."},{"key":"280_CR64","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4321\/S1885-642X2006000200001","volume":"4","author":"AE Omoti","year":"2006","unstructured":"Omoti AE, Omoti CE. Ocular toxicity of systemic anticancer chemotherapy. Pharm Pract (Granada). 2006;4:55\u20139.","journal-title":"Pharm Pract (Granada)."},{"key":"280_CR65","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-3-030-41008-7_17","volume":"1244","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Al-Zubidi N, Appelbaum E, Gombos DS, Nader ME, Gidley PW, et al. Immune-Related Oral, Otologic, and Ocular Adverse Events. Adv Exp Med Biol. 2020;1244:295\u2013307.","journal-title":"Adv Exp Med Biol."},{"key":"280_CR66","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/ICO.0b013e318183a3bd","volume":"28","author":"X Ding","year":"2009","unstructured":"Ding X, Bishop RJ, Herzlich AA, Patel M, Chan CC. Limbal stem cell deficiency arising from systemic chemotherapy with hydroxycarbamide. Cornea. 2009;28:221\u20133.","journal-title":"Cornea"},{"key":"280_CR67","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.ophtha.2014.04.025","volume":"121","author":"BY Kim","year":"2014","unstructured":"Kim BY, Riaz KM, Bakhtiari P, et al. Medically reversible limbal stem cell disease: clinical features and management strategies. Ophthalmology. 2014;121:2053\u20138.","journal-title":"Ophthalmology"},{"key":"280_CR68","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ophtha.2009.07.032","volume":"117","author":"A Lichtinger","year":"2010","unstructured":"Lichtinger A, Pe'er J, Frucht-Pery J, Solomon A. Limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia. Ophthalmology. 2010;117:431\u20137.","journal-title":"Ophthalmology"},{"key":"280_CR69","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.235937","author":"R Popat","year":"2020","unstructured":"Popat R, Warcel D, O'Nions J, et al. Characterisation of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. Haematologica. 2020. https:\/\/doi.org\/10.3324\/haematol.2019.235937.","journal-title":"Haematologica"}],"updated-by":[{"DOI":"10.1007\/s40123-020-00289-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000}}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-020-00280-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-020-00280-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-020-00280-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T23:09:06Z","timestamp":1627168146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-020-00280-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1007\/s40123-020-00280-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40123-020-00289-z","asserted-by":"object"}]},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,25]]},"assertion":[{"value":"21 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2020","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors of the above mentioned article would like to highlight the following corrections, based upon recent changes to the FDA label and guidance on the use of belamaf","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article was revised to update the Digital features link.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article was revised to correct the Digital features hyperlink.","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}